ODYY - Odyssey Group International, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.6500
-0.0300 (-4.41%)
At close: 3:56PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.6800
Open0.6810
BidN/A x N/A
AskN/A x N/A
Day's Range0.6460 - 0.7100
52 Week Range0.6356 - 8.0000
Volume204,822
Avg. Volume94,720
Market Cap56.661M
Beta (5Y Monthly)3.15
PE Ratio (TTM)N/A
EPS (TTM)-0.0600
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • ACCESSWIRE

    Odyssey Group International Issues Statement Regarding Unauthorized Promotional Activity Involving its Common Stock

    IRVINE, CA / ACCESSWIRE / June 11, 2020 / Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, learned about certain promotional activity involving the trading of its common stock on June 9, 2020 when it was notified of such activity by OTC Markets ("OTC"). At that time, the Company was informed that promotional articles were published on the internet by a non-affiliated third-party source. The source of the promotional activity was two (2) online articles, by "MicroCapDaily" and "InsiderFinancial".

  • ACCESSWIRE

    Odyssey Group International Strengthens Balance Sheet

    IRVINE, CA / ACCESSWIRE / June 9, 2020 / Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to announce that Vivakor, Inc. and existing note holder, has agreed and executed documents to convert the balance of its convertible note in the amount of $805,953.68 into equity of Odyssey. The agreed upon conversion is a price of $1.00 per common share.

  • ACCESSWIRE

    Odyssey Group International Provides Update on the Development of its Save a Life Choking Rescue Device

    Plans to File for Additional Patents Around Unique Designs IRVINE, CA / ACCESSWIRE / May 14, 2020 / Odyssey Group International, Inc. (OTCQB: ODYY ) (the "Company" or "Odyssey"), a ...

  • ACCESSWIRE

    Odyssey Group International Provides Progress Update on its Life-Saving Medical Products

    Files Quarterly Report for the Three Months Ended January 31, 2020 IRVINE, CA / ACCESSWIRE / March 31, 2020 / Odyssey Group International, Inc. (OTCQB: ODYY ) (the "Company" or "Odyssey"), ...

  • ACCESSWIRE

    Odyssey Group International Signs Agreement with Majic LLC

    IRVINE, CA / ACCESSWIRE / March 2, 2020 / Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced today announced it has signed an agreement with Majic LLC, based in Salem, New Hampshire. Majic, specializes in Systems Engineering, of medical devices, which encompasses integrating software, hardware, regulatory and manufacturing to insure consistent quality in high volume production. Majic will implement its Systems Engineering approach to assist Odyssey on both CardioMap and Save a Life choking rescue device, and to ensure the products are integrated properly and address all regulatory requirements.

  • ACCESSWIRE

    Odyssey Group International Appoints Mike Contarino to Lead Product Development Programs

    IRVINE, CA / ACCESSWIRE / February 10, 2020 / Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to announce the appointment of Mike Contarino as its Head of Product Development. Mike is the ideal person to take charge of our commercialization efforts with his 30 years of experience running large medical device product development programs.

  • ACCESSWIRE

    Odyssey Group International and Prevacus Provide Development Update on its Potential Concussion and Nieman Picks Drug Candidates

    GMP Certification Completed IRVINE, CA / ACCESSWIRE / January 29, 2020 / Odyssey Group International, Inc. (OTCQB: ODYY ) (the "Company" or "Odyssey"), a technology and asset acquisition ...

  • ACCESSWIRE

    Odyssey Group International Initiates Development of Personal Cardiac Mobile Device

    IRVINE, CA / ACCESSWIRE / January 22, 2020 / Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced that it has entered into a development agreement with the inventor of the current CardioMap technology to design and develop the next generation device. CardioMap was originally designed for doctor's offices and hospitals, but can be easily transformed for personal use or alternative setting (gyms, spa's, home, ambulatory care and/or clinics). The current technology is much more sensitive and accurate than traditional EKG technology.

  • ACCESSWIRE

    Odyssey Group International Enters Product Development Agreement for its Save a Life Choking Rescue Device

    Product Development and Design Agreement with Tanaka Kapec Design Group IRVINE, CA / ACCESSWIRE / January 15, 2020 / Odyssey Group International, Inc. (OTCQB: ODYY ) (the "Company" or "Odyssey"), ...

  • ACCESSWIRE

    Odyssey Group International Up-Lists and Begins Trading on the OTCQB

    Shareholder Equity Increased to $22.4 Million IRVINE, CA / ACCESSWIRE / December 4, 2019 / Odyssey Group International, Inc. (OTCQB: ODYY ) (the "Company" or "Odyssey"), a technology ...

  • ACCESSWIRE

    Odyssey and Prevacus Expand Partnership for Rare Brain Disorders

    IRIVINE, CA / ACCESSWIRE / September 9, 2019 / Odyssey Group International, Inc. (OTC Pink:ODYY), a technology and asset acquisition company focused on developing unique, life saving medical products has expanded its partnership with Prevacus Inc. In June, 2019 Prevacus, Inc. and Odyssey Group International, Inc. entered into a joint venture agreement to develop a proprietary neurosteroid for treating pediatric Niemann Pick Type C Disease. Recently the two companies have agreed to expand the partnership to include other leukodystrophies such as Krabbe disease and Metachromatic Leukodystrophy.

  • ACCESSWIRE

    Odyssey Group International Appoints New Board Member

    Industry veteran, Jeff Conroy, joins Board of Directors IRVINE, CA / ACCESSWIRE / September 4, 2019 / Odyssey Group International, Inc. (OTC PINK: ODYY ), a technology and asset acquisition company focused ...